| Literature DB >> 25845933 |
Erzsébet Mernyák1, Ida Kovács2, Renáta Minorics2, Péter Sere3, Dóra Czégány3, Izabella Sinka2, János Wölfling3, Gyula Schneider3, Zsuzsanna Újfaludi4, Imre Boros4, Imre Ocsovszki5, Mónika Varga6, István Zupkó7.
Abstract
Novel 16-triazoles in the 13α-estrone series were synthesized via Cu(I)-catalyzed azide-alkyne cycloaddition of the two diastereomeric (on C-16 and on C-17) 16-azido-13α-estra-1,3,5(10)-trien-17-ol 3-benzyl ethers with substituted phenylacetylenes. The new heterocyclic derivatives were evaluated in vitro by means of MTT assays for antiproliferative activity against a panel of human adherent cancer cell lines (HeLa, MCF-7, A431, A2780, T47D, MDA-MB-231 and MDA-MB-361). The inversion of the configurations at C-16 and C-17 selectively affected the growth-inhibitory properties of the tested compounds. The 16β,17α isomers generally proved to be potent on all cell lines, with IC50 values comparable to those of the reference agent cisplatin. Change of the substitution pattern of the phenyl group of the acetylene led to great differences in antiproliferative properties. Exclusively the p-phenyl-substituted triazoles exerted high cytostatic effects. One of the most potent compounds activated caspase-3 and caspase-9 without influencing caspase-8, confirming the induction of apoptosis via the intrinsic pathway.Entities:
Keywords: 13α-estradiol; Antiproliferative effect; Apoptosis; Azide–alkyne cycloaddition; Cell cycle blockade
Mesh:
Substances:
Year: 2015 PMID: 25845933 DOI: 10.1016/j.jsbmb.2015.04.001
Source DB: PubMed Journal: J Steroid Biochem Mol Biol ISSN: 0960-0760 Impact factor: 4.292